By notice dated October 7, 2003, and published in the Federal Register on October 29, 2003, (68 FR 61699), Guilford Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in Schedule II.
The firm plans to manufacture a Schedule II cocaine derivative as a final intermediate for the production of dopascan injection.
No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Guilford Pharmaceuticals, Inc. to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Guilford Pharmaceuticals, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.
Dated: May 26, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-13537 Filed 6-15-04; 8:45 am]
BILLING CODE 4410-09-M